Leukemia & Lymphoma最新文献_第5页

Exploring the role of neutrophil extracellular traps in leukemia: a comprehensive review. 探讨中性粒细胞胞外陷阱在白血病中的作用：综述。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 DOI: 10.1080/10428194.2025.2547990

Ayat Abbasi-Shahkouh, Kimiya Rashidan, Abbas Azadmehr, Amir Atashi

引用次数: 0

CAR-T cell-associated neurotoxicity during therapy of hematologic malignancies: incidence, clinical features, predictive biomarkers and management measures. 恶性血液病治疗期间CAR-T细胞相关的神经毒性：发病率、临床特征、预测性生物标志物和管理措施

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-06-11 DOI: 10.1080/10428194.2025.2502810

R Velasco, I Abad-Inchaurrondo, A Sureda

{"title":"CAR-T cell-associated neurotoxicity during therapy of hematologic malignancies: incidence, clinical features, predictive biomarkers and management measures.","authors":"R Velasco, I Abad-Inchaurrondo, A Sureda","doi":"10.1080/10428194.2025.2502810","DOIUrl":"10.1080/10428194.2025.2502810","url":null,"abstract":"Chimeric antigen receptor T-cell therapy (CAR-T cell therapy)-associated neurotoxicity includes a range of neurological side effects following CAR-T cell infusion. While ICANS is already a well-recognized, widely described neurological complication, the spectrum of neurological toxicities associated with CAR-T cell therapy has widened to include other, less common but emerging neurotoxicity syndromes. These have been observed with its broader use and the development of new agents. Movement and neurocognitive toxicity represent a recently described and challenging syndrome associated with BCMA-directed CAR-T cell therapies. Cranial and peripheral neuropathies, as well as myelopathy have increasingly been identified. Rare forms of cerebellar toxicity have been described with under development agents as well. Furthermore, strokes or tumor inflammation-associated syndrome (TIAN) in patients with CNS disease may elicit an emergency consultation. Finally, classical forms of acute toxic leukoencephalopathy have been described in a few patients receiving fludarabine as lymphodepleting treatment before CAR-T cell infusion. These forms of neurotoxicity vary in severity, with some cases being severe and even life-threatening in the context of CAR-T cell therapy. The present review summarizes several types of neurotoxicity associated with CAR-T cell therapy in patients with hematologic malignancies, focusing on available data on incidence, clinical presentation, prediction, diagnostics and therapeutic management.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1557-1569"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Double hit lymphoma masqueraded as clusters of crater-like nonhealing infectious skin lesions. 双重打击淋巴瘤伪装成群集的坑样不愈合感染性皮肤病变。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-09 DOI: 10.1080/10428194.2025.2503464

Kerem Balan, Muhammed Aslan, Emine Arzu Ayhan, Serkan Akın, Furkan Aydın, Duygu Gülseren

引用次数: 0

Clinicopathological and global methylation profiling of acute myeloid leukemia with mutations in NPM1 and clonal hematopoiesis-related genes. NPM1和克隆造血相关基因突变的急性髓系白血病的临床病理和整体甲基化分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-04-25 DOI: 10.1080/10428194.2025.2495105

Mostafa Elhodaky, Drew Duckett, Lucas Santana-Santos, Timothy S Oh, Yasmin Abaza, Madina Sukhanova, Xinyan Lu, Erica R Vormittag-Nocito, Lawrence J Jennings, Juehua Gao

{"title":"Clinicopathological and global methylation profiling of acute myeloid leukemia with mutations in NPM1 and clonal hematopoiesis-related genes.","authors":"Mostafa Elhodaky, Drew Duckett, Lucas Santana-Santos, Timothy S Oh, Yasmin Abaza, Madina Sukhanova, Xinyan Lu, Erica R Vormittag-Nocito, Lawrence J Jennings, Juehua Gao","doi":"10.1080/10428194.2025.2495105","DOIUrl":"10.1080/10428194.2025.2495105","url":null,"abstract":"Recent studies suggest that nucleophosmin 1 (NPM1)-mutated acute myeloid leukemia (NPM1-AML) often arises from clonal hematopoiesis (CH) involving mutations in DTA genes (DNMT3A, TET2, ASXL1), which can persist during remission. This research evaluates the clinical implications of molecular profiling of CH-related DTA genes in NPM1-AML by comparing clinical features, treatment outcomes, and methylation patterns with those of NPM1-AML lacking DTA mutations. Findings show NPM1-AML with DTA mutations exhibited higher WBC/peripheral blood blast counts, a lower incidence of extramedullary disease, more frequent IDH2 but less FLT3-TKD mutations. However, no significant differences in clinical characteristics such as age, treatment response, or disease outcome between the groups were seen. Additionally, despite variations in methylation profiles based on disease status, no distinct differences between DTA-positive and negative groups were observed. Notably, three probes, including one linked to the FAM65B promoter, effectively differentiated disease states, highlighting the potential role of FAM65B in leukemogenesis and patient survival.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1661-1668"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

KR-acking the code in non-GCB DLBCL? 在非gcb DLBCL中包装代码？

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-08-03 DOI: 10.1080/10428194.2025.2541303

Adrian Minson, Jeremy Abramson

引用次数: 0

AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia. AP2M1是急性髓系白血病中与细胞周期阻滞和肿瘤免疫微环境相关的预后标志物。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-19 DOI: 10.1080/10428194.2025.2504161

Ce Shi, Yang Li, Xing Zou, Dayong Yao, Jia Wei, Zhiyu Liu, Yue Su, Boqian Yu, Xin Zhang, Zhenkun Wang, Hui Liang, Hao Gang, Yanhong Zhao, Mengmeng Gu

引用次数: 0

Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma. 青少年和青年霍奇金淋巴瘤患者的治疗时间差异及其对总生存率的影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-08 DOI: 10.1080/10428194.2025.2499607

Carlos A Cruz, Elizabeth R Rodriguez, Maanvi Thawani, Margaret Mazer, Matthew Hayhurst, Madison Swanson, Alexis Romero, J Andrew Livingston, Greg Aune, Debra Eshelman-Kent, Branko Cuglievan, Michael E Roth, Sairah Ahmed, Karen Albritton, Michelle A T Hildebrandt

{"title":"Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma.","authors":"Carlos A Cruz, Elizabeth R Rodriguez, Maanvi Thawani, Margaret Mazer, Matthew Hayhurst, Madison Swanson, Alexis Romero, J Andrew Livingston, Greg Aune, Debra Eshelman-Kent, Branko Cuglievan, Michael E Roth, Sairah Ahmed, Karen Albritton, Michelle A T Hildebrandt","doi":"10.1080/10428194.2025.2499607","DOIUrl":"10.1080/10428194.2025.2499607","url":null,"abstract":"Delays in time to treatment (TTT) have been shown to affect cancer survival, yet this has not been investigated in adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients. This retrospective analysis included 508 patients with TTT defined as the time between diagnosis and chemotherapy start. The median TTT for the population was 28 days (IQR: 12-44). Patients who reported fevers and night sweats had shorter TTT than those who did not (p = 0.016 and p = 0.017, respectively). TTT varied significantly by age group (p < 0.01), with adolescents (15-18 years) having nearly a 10-day shorter TTT (21.3 days) compared to a TTT of 30.2 and 31.2 days for emerging adults (19-25 years) and young adults (26-39 years), respectively. Delayed TTT was not associated with risk of death. The lack of association with survival may reflect the overall favorable survival experienced by AYA HL patients and is in line with that reported for HL across all age populations.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1720-1726"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. 扎努鲁替尼与阿卡拉布替尼间接治疗复发或难治性套细胞淋巴瘤的比较。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 DOI: 10.1080/10428194.2025.2541911

Bijal Shah, Swetha Challagulla, Sheng Xu, Rhys Williams, Shijie Ren, Tushar Srivastava, Raju Gautam, Keri Yang, Nakhle S Saba, Constantine S Tam

{"title":"Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.","authors":"Bijal Shah, Swetha Challagulla, Sheng Xu, Rhys Williams, Shijie Ren, Tushar Srivastava, Raju Gautam, Keri Yang, Nakhle S Saba, Constantine S Tam","doi":"10.1080/10428194.2025.2541911","DOIUrl":"https://doi.org/10.1080/10428194.2025.2541911","url":null,"abstract":"Zanubrutinib and acalabrutinib have demonstrated efficacy in separate single-arm clinical trials in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Given these single-arm trials lacked a common comparator, an unanchored indirect treatment comparison was conducted to assess the comparative efficacy of zanubrutinib versus acalabrutinib using a simulated treatment comparison (STC) method. In the base case analysis (adjusted for all covariates), zanubrutinib treatment was associated with significantly improved progression-free survival (hazard ratio [HR], 0.57 [95% confidence interval [CI], 0.35-0.94]; p = 0.0272) and overall survival (HR, 0.43 [95% CI, 0.23-0.82]; p = 0.0105) versus acalabrutinib. Overall response rate was numerically higher with zanubrutinib versus acalabrutinib (odds ratio [OR], 2.05 [95% CI, 0.72-5.84]; p = 0.1798). Sensitivity analyses, including a subset of covariates, provided consistent results. In the absence of a head-to-head trial, these results provide important insights into the comparative efficacy of zanubrutinib and acalabrutinib for physicians managing patients with R/R MCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment. 服用苯二氮卓类药物治疗naïve慢性淋巴细胞白血病患者与首次治疗时间较短有关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-05-15 DOI: 10.1080/10428194.2025.2504155

Tamar Tadmor, Gal Lavie, Guy Melamed, Hilel Alapi, Lior Rokach

{"title":"Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment.","authors":"Tamar Tadmor, Gal Lavie, Guy Melamed, Hilel Alapi, Lior Rokach","doi":"10.1080/10428194.2025.2504155","DOIUrl":"10.1080/10428194.2025.2504155","url":null,"abstract":"Patients after diagnosis of leukemia face midlife crisis. In some instances, it may be accompanied by anxiety or depression, which may require pharmacological intervention. In this study, we explored the association between benzodiazepine (BZP) usage and time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL) under a watch-and-wait (W&W) approach. Utilizing data from Maccabi Healthcare Services in Israel, we analyzed 3,474 CLL patients, focusing on BZP and non-BZP users. 330 patients (9.5%) received a BZP agent for a minimum of 3 months. Among BZP users, the ten years treatment free ratio is 83.4%, while among non-BZP users it is 90.7%. Through inverse probability and time-dependent Cox proportional models, we observed that BZP usage was significantly associated with a shorter TTFT (HR 1.78, p = 0.029). Our study suggested BZP usage, is associated with shorter TTFT. While an association was observed, causality cannot be confirmed, and further studies are needed to validate the hypothetical association and clarify the underlying mechanisms and clinical implications.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1682-1687"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia. b细胞急性淋巴细胞白血病单克隆抗体的研究进展。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-01 Epub Date: 2025-06-02 DOI: 10.1080/10428194.2025.2507198

Hamideh Kamalloo, Mahnaz Fathi, Sobhan Bavandi, Fereshteh Asadi, Sheida Janati, Kumars Amini

{"title":"Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia.","authors":"Hamideh Kamalloo, Mahnaz Fathi, Sobhan Bavandi, Fereshteh Asadi, Sheida Janati, Kumars Amini","doi":"10.1080/10428194.2025.2507198","DOIUrl":"10.1080/10428194.2025.2507198","url":null,"abstract":"Monoclonal antibody (mAb)-based therapies targeting CD19, CD20, and CD22 have revolutionized B-ALL treatment, offering precision and reduced systemic toxicity by engaging immune mechanisms to eliminate leukemic cells. This review synthesizes literature from PubMed, Web of Science, and ClinicalTrials.gov (2000-2024), focusing on clinical outcomes and resistance mechanisms. Bispecific T-cell engagers (e.g. blinatumomab) and CD22-directed antibody-drug conjugates (e.g. inotuzumab ozogamicin) demonstrate robust efficacy in relapsed/refractory disease. Advances in antibody engineering, such as Fc optimization, nanobodies, and humanization, enhance tumor targeting and therapeutic safety. Persistent challenges include antigen escape, stromal-mediated resistance, and treatment-related toxicities. Combinatorial approaches integrating mAbs with CAR-T cells or checkpoint inhibitors show promise in overcoming resistance pathways. Emerging technologies like artificial intelligence and deep learning are transforming antibody design by predicting epitope binding, enabling de novo protein engineering, and streamlining affinity maturation. These innovations accelerate the development of next-generation therapies, underscoring the evolving potential of precision immunotherapy of B-ALL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1570-1582"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0